Infectious disease
Documents related to the COVID-19 vaccine developed by Pfizer and BioNTech that were in possession of the European Medicines Agency have been accessed by hackers.
Vaccines are on the cusp of being authorized for use against COVID-19, but there is still a significant need for other therapeutics that will help patients who contract the virus fight off the devastating effects of the disease.
The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning.
UK regulators stated today that they have received two reports of potential allergic reactions linked to the COVID-19 vaccine from Pfizer and BioNTech.
Although vaccines will be available pending approval, there are questions as to how many people will quickly receive the vaccine and when more will be available.
AstraZeneca and the University of Oxford published an interim analysis of their four Phase III clinical trials of AZD1222, their COVID-19 vaccine.
President Donald Trump signed an Executive Order on Tuesday that ensures the U.S. government prioritizes delivery of COVID-19 vaccines to American citizens before sending it to other nations.
The document prepared and released by FDA staff indicates scientists from the agency plan to tell the advisory committee on Thursday that the available clinical trial data are adequate to support its safe and effective use in public immunization programs.
President Trump has repeatedly assured U.S. citizens his administration would secure enough COVID-19 vaccine doses to protect the nation. However, a new report shows his government failed to act in securing additional doses of Pfizer and BioNTech’s vaccine this summer.
BioSpace spoke with a few companies that have some ingenious ideas at different stages of preclinical and clinical development.
PRESS RELEASES